HUS
MCID: HML001
MIFTS: 53

Hemolytic-Uremic Syndrome (HUS)

Categories: Blood diseases, Immune diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hemolytic-Uremic Syndrome

MalaCards integrated aliases for Hemolytic-Uremic Syndrome:

Name: Hemolytic-Uremic Syndrome 12 76 29 55 6 44 15 73
Hemolytic Uremic Syndrome 12 53
Acute Renal Failure, Thrombocytopenia, and Microangiopathic Hemolytic Anemia Associated with Distorted Erythrocytes 53
Haemolytic-Uraemic Syndrome 12
Hus 53

Classifications:



External Ids:

Disease Ontology 12 DOID:12554
ICD10 33 D59.3
ICD9CM 35 283.11
MeSH 44 D006463
NCIt 50 C75545
UMLS 73 C0019061

Summaries for Hemolytic-Uremic Syndrome

NIH Rare Diseases : 53 Hemolytic uremic syndrome (HUS) is a disorder that usually occurs when an  E. coli bacterial infection in the digestive system produces toxic substances that destroy red blood cells. Symptoms include vomiting and diarrhea, fever, lethargy, and weakness. In severe cases it can lead to kidney failure or death. While this condition is most common in children, it often has a more complicated presentation in adults. Treatment may include dialysis, corticosteroids, transfusions of packed red blood cells and plasmapheresis.   Hemolytic uremic syndrome should be distinguished from atypical hemolytic uremic syndrome (aHUS). The two conditions have different causes and different signs and symptoms.

MalaCards based summary : Hemolytic-Uremic Syndrome, also known as hemolytic uremic syndrome, is related to nephrotic syndrome, type 7 and hemolytic uremic syndrome, atypical 1. An important gene associated with Hemolytic-Uremic Syndrome is DGKE (Diacylglycerol Kinase Epsilon), and among its related pathways/superpathways are Creation of C4 and C2 activators and Formation of Fibrin Clot (Clotting Cascade). The drugs Complement System Proteins and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and liver, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A kidney disease that is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs.

Wikipedia : 76 Hemolytic-uremic syndrome (HUS) is a disease characterized by a triad of hemolytic anemia (anemia caused... more...

Related Diseases for Hemolytic-Uremic Syndrome

Diseases in the Hemolytic-Uremic Syndrome family:

D-Plus Hemolytic Uremic Syndrome

Diseases related to Hemolytic-Uremic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 360)
# Related Disease Score Top Affiliating Genes
1 nephrotic syndrome, type 7 33.7 CFH DGKE
2 hemolytic uremic syndrome, atypical 1 33.1 ADAMTS13 C3 CD46 CFB CFH CFHR1
3 complement factor h deficiency 32.8 CD46 CFH CFHR1 CFI
4 purpura 31.1 ADAMTS13 F3 THBD VWF
5 glomerulonephritis 30.9 C3 CD46 CFH CFHR5 CFI
6 thrombotic thrombocytopenic purpura 30.8 ADAMTS13 CD46 CFH F3 THBD VWF
7 proliferative glomerulonephritis 30.7 C3 CFH
8 c3 glomerulopathy 30.6 C3 CFB CFHR1 CFHR3 CFHR5
9 membranoproliferative glomerulonephritis 30.5 C3 CD46 CFB CFH CFHR5
10 neisseria meningitidis infection 30.4 C3 CD46
11 thrombophilia 30.3 F3 THBD VWF
12 vasculitis 30.3 CFI THBD VWF
13 disseminated intravascular coagulation 30.3 ADAMTS13 F3 THBD
14 hemolytic anemia 30.0 ADAMTS13 C3 CFH CFI HP
15 catastrophic antiphospholipid syndrome 30.0 ADAMTS13 CFH F3
16 hemophilia 29.9 F3 VWF
17 evans' syndrome 29.9 ADAMTS13 HP
18 hemophilia a 29.9 F3 VWF
19 von willebrand's disease 29.9 ADAMTS13 F3 VWF
20 thrombotic thrombocytopenic purpura, congenital 29.8 ADAMTS13 CFH HP
21 hepatic veno-occlusive disease 29.7 F3 THBD
22 malaria 29.7 ADAMTS13 F3 HP THBD VWF
23 pulmonary hypertension 29.7 F3 THBD VWF
24 antiphospholipid syndrome 29.6 ADAMTS13 F3 THBD VWF
25 enterocolitis 29.6 C3 CD46 CFB CFH CFHR1 CFHR3
26 stroke, ischemic 29.6 ADAMTS13 F3 THBD VWF
27 korean hemorrhagic fever 29.5 F3 VWF
28 systemic lupus erythematosus 29.4 ADAMTS13 C3 CFB CFH F3 THBD
29 macular degeneration, age-related, 1 29.4 C3 CD46 CFB CFH CFHR1 CFHR3
30 essential thrombocythemia 29.4 F3 THBD VWF
31 hellp syndrome 29.1 ADAMTS13 CD46 CFH CFI F3 HP
32 hemolytic uremic syndrome, atypical 3 12.8
33 hemolytic uremic syndrome, atypical 4 12.8
34 hemolytic uremic syndrome, atypical 5 12.8
35 hemolytic uremic syndrome, atypical 6 12.8
36 hemolytic uremic syndrome, atypical 2 12.8
37 hemolytic uremic syndrome, atypical, childhood 12.7
38 genetic atypical hemolytic-uremic syndrome 12.5
39 d-minus hemolytic uremic syndrome 12.4
40 d-plus hemolytic uremic syndrome 12.4
41 atypical hemolytic-uremic syndrome with h factor anomaly 12.4
42 shigellosis 11.8
43 combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia 11.5
44 pancreatitis, pediatric 11.3
45 dupuytren contracture 11.2
46 gastroesophageal reflux 11.0
47 retinitis pigmentosa 3 11.0
48 diarrhea 10.8
49 encephalopathy 10.6
50 colitis 10.5

Comorbidity relations with Hemolytic-Uremic Syndrome via Phenotypic Disease Network (PDN):


Acute Kidney Failure Chronic Kidney Failure
Deficiency Anemia Heart Disease

Graphical network of the top 20 diseases related to Hemolytic-Uremic Syndrome:



Diseases related to Hemolytic-Uremic Syndrome

Symptoms & Phenotypes for Hemolytic-Uremic Syndrome

MGI Mouse Phenotypes related to Hemolytic-Uremic Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 ADAMTS13 C3 CABIN1 CFB CFH CFI
2 immune system MP:0005387 9.61 ADAMTS13 C3 CABIN1 CFB CFH F3
3 renal/urinary system MP:0005367 9.1 C3 CFB CFH CFI HP THBD

Drugs & Therapeutics for Hemolytic-Uremic Syndrome

Drugs for Hemolytic-Uremic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Complement System Proteins Phase 2, Phase 3,Phase 3
2 Immunologic Factors Phase 3,Phase 2
3 Shiga Toxins Phase 2, Phase 3,Phase 3,Phase 1
4 Antibodies Phase 3,Phase 2
5 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1,Not Applicable
6 Immunoglobulins Phase 3,Phase 2
7 Complement Inactivating Agents Phase 3
8 Coagulants Phase 3
9 Factor VIII Phase 3
10 Antibodies, Bispecific Phase 3
11
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
12
Promethazine Approved, Investigational Phase 2 60-87-7 4927
13
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
14
Acetaminophen Approved Phase 2 103-90-2 1983
15
rituximab Approved Phase 2 174722-31-7 10201696
16
Vinblastine Approved Phase 2 865-21-4 241903 13342
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3
19
Everolimus Approved Phase 2 159351-69-6 6442177
20
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
21
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
22
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
25 Antirheumatic Agents Phase 2
26 Antibodies, Monoclonal Phase 2
27 Anti-Infective Agents Phase 2
28 Antineoplastic Agents, Phytogenic Phase 2
29 Antibiotics, Antitubercular Phase 2
30 Immunoglobulin G Phase 2
31 Alkylating Agents Phase 2
32 Antimitotic Agents Phase 2
33 Angiogenesis Modulating Agents Phase 2
34 Anti-Bacterial Agents Phase 2
35 Immunosuppressive Agents Phase 2
36 Antifungal Agents Phase 2
37 Mitogens Phase 2
38 Endothelial Growth Factors Phase 2
39 Antineoplastic Agents, Alkylating Phase 2
40 Angiogenesis Inhibitors Phase 2
41 Immunotoxins Phase 2
42 BB 1101 Phase 2
43
Metoclopramide Approved, Investigational Not Applicable 364-62-5 4168
44 dipyrone Not Applicable
45 Natriuretic Peptide, Brain Not Applicable
46 Natriuretic Agents Not Applicable
47 Antibodies, Blocking

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
2 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
3 Erythropoietin in Hemolytic Uremic Syndrome Not yet recruiting NCT03776851 Phase 4 erythropoietin
4 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
5 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Completed NCT02205541 Phase 3 Eculizumab;Placebo
6 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03205995 Phase 3
7 Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT03131219 Phase 3
8 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia Recruiting NCT03362970 Phase 3
9 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Active, not recruiting NCT02949128 Phase 3
10 A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Active, not recruiting NCT03191799 Phase 3 Emicizumab
11 Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome Terminated NCT00004465 Phase 3 SYNSORB Pk;Placebo
12 The Plasma Large-Volume Exchange RCT Withdrawn NCT01433003 Phase 3
13 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
14 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed NCT01194973 Phase 2 Eculizumab
15 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed NCT01193348 Phase 2 Eculizumab
16 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT00838513 Phase 2 eculizumab
17 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed NCT00844545 Phase 2 Eculizumab
18 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed NCT00844844 Phase 2 Eculizumab
19 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed NCT00844428 Phase 2 eculizumab
20 The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01757431 Phase 2 Eculizumab
21 Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2 Completed NCT01252199 Phase 2 cαStx1/cαStx2;Placebo
22 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
23 Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) Completed NCT01030536 Phase 1, Phase 2 CAT-8015 20 mcg/kg;CAT-8015 30 mcg/kg;CAT-8015 40 mcg/kg;CAT-8015 50 mcg/kg;CAT-8015 60 mcg/kg
24 Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Recruiting NCT03518203 Phase 2 Eculizumab
25 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Recruiting NCT02222545 Phase 2
26 Complement Inhibition in aHUS Dialysis Patients Terminated NCT02464891 Phase 2 CCX168
27 Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT02338050 Phase 2
28 A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Withdrawn NCT03303313 Phase 2 Cemdisiran
29 Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion Not yet recruiting NCT03275792 Phase 1 D5-0.9%NS;Routine home oral rehydration
30 Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease Unknown status NCT00930423
31 Study of 'Vascular Competence' Profile and Endothelial Activation in the Hemolytic Uremic Syndrome in Children and Adults Unknown status NCT02904863 Not Applicable
32 Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 Completed NCT01406288
33 A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01770951
34 Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects Completed NCT01666548
35 To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients Completed NCT01755429
36 Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis Completed NCT01561248 Not Applicable polyethylene glycol solution for daily bowel lavage.
37 The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury) Completed NCT00358306
38 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
39 Early Predictive Factors of Cardiac and Cerebral Involvement in TMA Completed NCT02134171 Not Applicable
40 Atypical Hemolytic-Uremic Syndrome (aHUS) Registry Recruiting NCT01522183
41 TTP and aHUS in Complicated Pregnancies Recruiting NCT03605511
42 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
43 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment Recruiting NCT01087333
44 Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series Active, not recruiting NCT03574506
45 Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy Active, not recruiting NCT03580941
46 The Role of Microparticles as a Biomarker Enrolling by invitation NCT02626663
47 Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital Not yet recruiting NCT03690024
48 aHUS Observational Long Term Follow-Up Terminated NCT01522170
49 International Registry and Biorepository for TMA(Thrombotic Microangiopathy) Terminated NCT00593229

Search NIH Clinical Center for Hemolytic-Uremic Syndrome

Cochrane evidence based reviews: hemolytic-uremic syndrome

Genetic Tests for Hemolytic-Uremic Syndrome

Genetic tests related to Hemolytic-Uremic Syndrome:

# Genetic test Affiliating Genes
1 Hemolytic-Uremic Syndrome 29

Anatomical Context for Hemolytic-Uremic Syndrome

MalaCards organs/tissues related to Hemolytic-Uremic Syndrome:

41
Kidney, Endothelial, Liver, Heart, Lung, B Cells, Testes

Publications for Hemolytic-Uremic Syndrome

Articles related to Hemolytic-Uremic Syndrome:

(show top 50) (show all 1263)
# Title Authors Year
1
Hemolytic Uremic Syndrome. ( 30454746 )
2019
2
Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. ( 29215813 )
2018
3
Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia. ( 29858280 )
2018
4
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype andA outcome. ( 29907460 )
2018
5
Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). ( 29372302 )
2018
6
Atypical Presentation of Pregnancy-Related Hemolytic Uremic Syndrome. ( 29331477 )
2018
7
Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy? ( 29808447 )
2018
8
An outbreak of hemolytic uremic syndrome in southern Romania during 2015-2016: Epidemiologic, clinical, laboratory, microbiologic, therapeutic and outcome characteristics. ( 29807724 )
2018
9
CCR2-dependent Gr1high monocytes promote kidney injury in shiga toxin-induced hemolytic uremic syndrome in mice. ( 29446073 )
2018
10
Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology. ( 29796581 )
2018
11
Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab. ( 29308213 )
2018
12
Atypical hemolytic uremic syndrome: An unusual postoperative complication. ( 29426622 )
2018
13
Gastrointestinal pathogens in anti-FH antibody positive and negative Hemolytic Uremic Syndrome. ( 29795200 )
2018
14
Thrombomodulin and Endothelial Dysfunction: A Disease-Modifier Shared between Malignant Hypertension and Atypical Hemolytic Uremic Syndrome. ( 29940557 )
2018
15
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. ( 29768958 )
2018
16
Poststreptococcal glomerulonephritis with atypical hemolytic uremic syndrome: An unusual presentation. ( 29970754 )
2018
17
C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. ( 29594148 )
2018
18
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. ( 29500241 )
2018
19
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. ( 29959568 )
2018
20
Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. ( 29356300 )
2018
21
50 Years Ago in The Journal of Pediatrics: The Hemolytic-Uremic Syndrome: Renal Status of 76 Patients at Long-Term Follow-Up. ( 29801537 )
2018
22
Atypical adult-onset methylmalonic acidemia and homocystinuria presenting as hemolytic uremic syndrome. ( 29294253 )
2018
23
Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. ( 29288280 )
2018
24
Atypical Hemolytic Uremic Syndrome. ( 29803280 )
2018
25
Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. ( 29961127 )
2018
26
A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. ( 29434134 )
2018
27
Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome. ( 29248304 )
2018
28
Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threating Life Complication. ( 29931191 )
2018
29
Hemolytic uremic syndrome caused by Aeromona caviae in a pediatric patient. ( 29779570 )
2018
30
Streptococcus pneumoniae-associated Hemolytic Uremic Syndrome. ( 29417459 )
2018
31
Gastrointestinal Bleeding after Hemolytic Uremic Syndrome: A Report of Drug-Associated Granulation Tissue Polyps. ( 29851764 )
2018
32
Experimental <i>in vivo</i> models of bacterial Shiga toxin-associated hemolytic uremic syndrome. ( 29926707 )
2018
33
Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes. ( 29979220 )
2018
34
Infant onset severe complement-mediated hemolytic uremic syndrome complicated by secondary sclerosing cholangitis. ( 30168181 )
2018
35
Erratum to Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threatening Complication. ( 30407527 )
2018
36
A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis. ( 30541482 )
2018
37
Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. ( 30251107 )
2018
38
Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort. ( 30368614 )
2018
39
ADAMTS-13 level in children with severe diarrhea-associated hemolytic uremic syndrome: Unmasking new association. ( 29657197 )
2018
40
Atypical Hemolytic Uremic Syndrome Presenting as Pre-eclampsia in a 24-year-old Woman with Chronic Kidney Disease: Pathogenesis and Genetics. ( 30510868 )
2018
41
An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment. ( 30344987 )
2018
42
Gastroenteritis in an adult female revealing hemolytic uremic syndrome: Case report. ( 29456415 )
2018
43
Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. ( 30031798 )
2018
44
Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. ( 30032752 )
2018
45
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. ( 30039480 )
2018
46
Hemolytic Uremic Syndrome: An Increasingly Recognized Public Health Problem. ( 30083060 )
2018
47
A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network. ( 30094644 )
2018
48
Hemolytic uremic syndrome and IgA nephropathy in a child: Coincidence or not? ( 30102484 )
2018
49
Extra-renal manifestations of atypical hemolytic uremic syndrome. ( 30109445 )
2018
50
Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. ( 30131950 )
2018

Variations for Hemolytic-Uremic Syndrome

ClinVar genetic disease variations for Hemolytic-Uremic Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 DGKE NM_003647.2(DGKE): c.888+40A> G single nucleotide variant Pathogenic GRCh38 Chromosome 17, 56848105: 56848105
2 DGKE NM_003647.2(DGKE): c.888+40A> G single nucleotide variant Pathogenic GRCh37 Chromosome 17, 54925466: 54925466

Expression for Hemolytic-Uremic Syndrome

Search GEO for disease gene expression data for Hemolytic-Uremic Syndrome.

Pathways for Hemolytic-Uremic Syndrome

GO Terms for Hemolytic-Uremic Syndrome

Cellular components related to Hemolytic-Uremic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.86 C3 CD46 CFB CFH CFHR3 CFI
2 extracellular region GO:0005576 9.85 ADAMTS13 C3 CFB CFH CFHR1 CFHR5
3 extracellular space GO:0005615 9.65 ADAMTS13 C3 CFB CFH CFHR1 CFHR3
4 blood microparticle GO:0072562 9.1 C3 CFB CFH CFHR1 CFHR3 HP

Biological processes related to Hemolytic-Uremic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.85 ADAMTS13 C3 CFB CFI HP
2 innate immune response GO:0045087 9.77 C3 CD46 CFB CFH CFI
3 complement activation, classical pathway GO:0006958 9.65 C3 CD46 CFI
4 blood coagulation GO:0007596 9.62 ADAMTS13 F3 THBD VWF
5 platelet activation GO:0030168 9.61 ADAMTS13 DGKE VWF
6 complement activation GO:0006956 9.56 C3 CFB CFH CFHR1
7 hemostasis GO:0007599 9.46 ADAMTS13 F3 THBD VWF
8 positive regulation of cytolysis GO:0045919 9.4 CFHR1 CFHR5
9 complement activation, alternative pathway GO:0006957 9.26 C3 CFB CFH CFHR5
10 regulation of complement activation GO:0030449 9.17 C3 CD46 CFB CFH CFHR1 CFHR5

Molecular functions related to Hemolytic-Uremic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.02 C3 CFB CFI F3 HP

Sources for Hemolytic-Uremic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....